Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

420
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
420
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology01:29

Gastroesophageal Reflux Disease I: Meaning and Pathophysiology

1.6K
Gastroesophageal Reflux Disease (GERD) involves the recurrent backflow of the stomach or duodenal contents into the esophagus, leading to troublesome symptoms and potential esophageal mucosal damage. Although GERD is often referred to as a disease, it is more accurately described as a syndrome, as it encompasses a range of symptoms and complications rather than a singular pathological entity, impacting a large number of individuals as the most prevalent upper gastrointestinal problem. Roughly...
1.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.4K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.4K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K
Diffusion01:12

Diffusion

217.9K
Diffusion is the passive movement of substances down their concentration gradients—requiring no expenditure of cellular energy. Substances, such as molecules or ions, diffuse from an area of high concentration to an area of low concentration in the cytosol or across membranes. Eventually, the concentration will even out, with the substance moving randomly but causing no net change in concentration. Such a state is called dynamic equilibrium, which is essential for maintaining overall...
217.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesothelial Plasticity Specifies a Pleural Immune Circuit that Orchestrates Lung Regeneration.

bioRxiv : the preprint server for biology·2026
Same author

Epigenetic de-repression of basal cell metaplasia in aging AT2 cells is a risk factor for idiopathic pulmonary fibrosis (IPF).

bioRxiv : the preprint server for biology·2026
Same author

Immortalization of Human Adult Alveolar Epithelial Cells to Study Environmental Exposures of the Distal Lung.

Current protocols·2026
Same author

The role of extracorporeal membrane oxygenation in the management of rapidly progressive interstitial lung disease due to anti-melanoma differentiation-associated gene 5 antibody dermatomyositis: A case series and brief literature review.

JHLT open·2026
Same author

Development and validation of a generalisable machine learning algorithm for identifying interstitial lung disease cohorts: a retrospective cohort study.

EClinicalMedicine·2026
Same author

Claudin 4 Deletion Improves Gut Permeability and Survival in a Murine Model of Abdominal Sepsis.

Shock (Augusta, Ga.)·2026

Related Experiment Video

Updated: Jan 29, 2026

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis
05:56

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis

Published on: August 9, 2024

2.5K

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Jisha Joshua1, Zea Borok1

  • 1Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, Department of Medicine, University of California San Diego, La Jolla, California, USA;

Annual Review of Medicine
|January 27, 2026
PubMed
Summary

Diffuse parenchymal lung disease (DPLD) management is challenging due to complex causes and diagnosis. Recent advances in understanding pathophysiology and multidisciplinary collaboration improve personalized treatment and patient outcomes for these fibrotic lung conditions.

Keywords:
connective tissue disease–associated interstitial lung diseasefibrosishypersensitivity pneumonitisidiopathic pulmonary fibrosisinterstitial lung diseaseusual interstitial pneumonia

More Related Videos

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

11.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.8K

Related Experiment Videos

Last Updated: Jan 29, 2026

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis
05:56

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis

Published on: August 9, 2024

2.5K
Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

11.1K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.8K

Area of Science:

  • Pulmonology
  • Internal Medicine

Background:

  • Diffuse parenchymal lung disease (DPLD) encompasses diverse inflammatory-fibrotic conditions with complex pathogenesis.
  • Heterogeneity in patients and non-specific diagnostic methods present significant management challenges.

Purpose of the Study:

  • To review recent advances in the epidemiology, classification, pathophysiology, and management of DPLD.
  • To highlight the impact of multidisciplinary collaboration on improving diagnostic accuracy and personalized treatment strategies.

Main Methods:

  • Literature review focusing on advancements in the last decade.
  • Analysis of current therapeutic options, including antifibrotics and symptom management.
  • Exploration of ongoing research for novel diagnostic and therapeutic approaches.

Main Results:

  • Multidisciplinary collaboration has enhanced DPLD diagnosis and personalized treatment, leading to improved patient outcomes.
  • Management strategies now include targeted therapies like antifibrotics and comprehensive symptom/comorbidity management.
  • Significant progress has been made in understanding DPLD pathophysiology.

Conclusions:

  • Recent advancements offer improved management and outcomes for DPLD patients.
  • Personalized treatment strategies, informed by multidisciplinary input, are crucial for managing DPLD subtypes.
  • Ongoing research promises new diagnostic tools and therapies for fibrotic lung diseases.